高原肺部疾病的发病机制及治疗药物

黄粤琪; 胡静璐; 李祺; 李淼; 谢菲; 杜丽娜; 金义光; 黄粤琪; 胡静璐; 李祺; 李淼; 谢菲; 杜丽娜; 金义光

doi:10.12206/j.issn.1006-0111.202111025

[1]

RIDOLO E, MARTIGNAGO I, MASIERI S. Mechanisms of allergic diseases in otorhinolaryngology[J]. J Biol Regul Homeost Agents, 2018, 32(1 Suppl. 1): 9-12.

[2]

李兵, 刘元东. 低海拔地区官兵急进高原及高原作业各阶段疾病谱调查[J]. 人民军医, 2018, 61(11):1012-1017,1020.

[3]

黄粤琪, 陈婷, 王婉梅, 等. 西地那非脂质体的制备及其肺部给药预防高原肺水肿的作用[J]. 药学学报, 2021, 56(10):2658-2668.

[4]

陈杨, 潘春光, 姜俊杰, 等. 高原肺水肿的发病机制及其防治研究进展[J]. 解放军预防医学杂志, 2018, 36(4):532-536.

[5]

BÄRTSCH P. High altitude pulmonary edema[J]. Respiration,1997,64(6):435-443. doi: 10.1159/000196720

[6]

HACKETT P, RENNIE D. High-altitude pulmonary edema[J]. JAMA,2002,287(17):2275-2278. doi: 10.1001/jama.287.17.2275

[7]

KUBO K, HANAOKA M, YAMAGUCHI S, et al. Cytokines in bronchoalveolar lavage fluid in patients with high altitude pulmonary oedema at moderate altitude in Japan[J]. Thorax,1996,51(7):739-742. doi: 10.1136/thx.51.7.739

[8]

轩银霜, 卞晴晴, 李亚, 等. 中药对肺部炎症性疾病水通道蛋白影响的实验研究进展[J]. 中药药理与临床, 2021, 37(2):221-227.

[9]

SCHANNWELL C M, STEINER S, STRAUER B E. Diagnostics in pulmonary hypertension[J]. J Physiol Pharmacol, 2007, 58 Suppl 5(Pt 2): 591-602.

[10]

SAOUTI N, WESTERHOF N, POSTMUS P E, et al. The arterial load in pulmonary hypertension[J]. Eur Respir Rev,2010,19(117):197-203. doi: 10.1183/09059180.00002210

[11]

RYBALKIN S D, YAN C, BORNFELDT K E, et al. Cyclic GMP phosphodiesterases and regulation of smooth muscle function[J]. Circ Res,2003,93(4):280-291. doi: 10.1161/01.RES.0000087541.15600.2B

[12]

BASNYAT B, MURDOCH D R. High-altitude illness[J]. Lancet,2003,361(9373):1967-1974. doi: 10.1016/S0140-6736(03)13591-X

[13]

POLLOCK D M. Endothelin, angiotensin, and oxidative stress in hypertension[J]. Hypertension,2005,45(4):477-480. doi: 10.1161/01.HYP.0000158262.11935.d0

[14]

BLOCH K E, TURK A J, MAGGIORINI M, et al. Effect of ascent protocol on acute mountain sickness and success at Muztagh Ata, 7546 M[J]. High Alt Med Biol,2009,10(1):25-32. doi: 10.1089/ham.2008.1043

[15]

DUMONT L, MARDIROSOFF C, TRAMÈR M R. Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review[J]. BMJ,2000,321(7256):267-272. doi: 10.1136/bmj.321.7256.267

[16]

YOUNG S L, HO Y S, SILBAJORIS R A. Surfactant apoprotein in adult rat lung compartments is increased by dexamethasone[J]. Am J Physiol, 1991, 260(2 Pt 1): L161-L167.

[17]

ELLSWORTH A J, MEYER E F, LARSON E B. Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier[J]. West J Med,1991,154(3):289-293.

[18]

URNER M, HERRMANN I K, BOOY C, et al. Effect of hypoxia and dexamethasone on inflammation and ion transporter function in pulmonary cells[J]. Clin Exp Immunol,2012,169(2):119-128. doi: 10.1111/j.1365-2249.2012.04595.x

[19]

SEKIYAMA A, GON Y, TERAKADO M, et al. Glucocorticoids enhance airway epithelial barrier integrity[J]. Int Immunopharmacol,2012,12(2):350-357. doi: 10.1016/j.intimp.2011.12.006

[20]

PLANÈS C, ESCOUBET B, BLOT-CHABAUD M, et al. Hypoxia downregulates expression and activity of epithelial sodium channels in rat alveolar epithelial cells[J]. Am J Respir Cell Mol Biol,1997,17(4):508-518. doi: 10.1165/ajrcmb.17.4.2680

[21]

杨伟, 王宇鹤, 杨永彦, 等. 高原脱适应的研究进展[J]. 西藏医药杂志, 2012, 33(2):1-3.

[22]

PENALOZA D, ARIAS-STELLA J. The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness[J]. Circulation,2007,115(9):1132-1146. doi: 10.1161/CIRCULATIONAHA.106.624544

[23]

LIU W, HUA S C, PENG L P. The application of bi-level positive airway pressure in patients with severe pneumonia and acute respiratory failure caused by influenza A (H1N1) virus[J]. J Thorac Dis,2010,2(3):134-137.

[24]

FLESSAS N, ALEXANIAN I, PARISSIS J, et al. Plasma activity of B-type natriuretic peptide in patients with biventricular heart failure versus those with right heart failure due to chronic obstructive pulmonary disease[J]. J Cardiovasc Med (Hagerstown),2014,15(6):476-480. doi: 10.2459/JCM.0000000000000007

[25]

ZHOU Q Q, YANG S Y, LUO Y J, et al. A randomly-controlled study on the cardiac function at the early stage of return to the Plains after short-term exposure to high altitude[J]. PLoS One,2012,7(2):e31097. doi: 10.1371/journal.pone.0031097

[26]

张旭, 陈旺盛, 冯健, 等. 银杏内酯B保护缺氧/复氧诱导心肌细胞损伤模型的作用及机制[J]. 中国组织工程研究, 2019, 23(19):3097-3101. doi: 10.3969/j.issn.2095-4344.1257

[27]

ARCHER S, RICH S. Primary pulmonary hypertension: a vascular biology and translational research “Work in progress”[J]. Circulation,2000,102(22):2781-2791. doi: 10.1161/01.CIR.102.22.2781

[28]

PICHIULE P, LAMANNA J C. Expression of angiopoietin-1 and -2 in the rat brain during chronic hypoxia and de-adaptation[J]. Adv Exp Med Biol,2003,510:331-335.

[29]

VEITH C, SCHERMULY R T, BRANDES R P, et al. Molecular mechanisms of hypoxia-inducible factor-induced pulmonary arterial smooth muscle cell alterations in pulmonary hypertension[J]. J Physiol,2016,594(5):1167-1177. doi: 10.1113/JP270689

[30]

SONG Q L, YIN Y J, SHANG L H, et al. Tumor microenvironment responsive nanogel for the combinatorial antitumor effect of chemotherapy and immunotherapy[J]. Nano Lett,2017,17(10):6366-6375. doi: 10.1021/acs.nanolett.7b03186

[31]

MONCADA S, GRYGLEWSKI R, BUNTING S, et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation[J]. Nature,1976,263(5579):663-665. doi: 10.1038/263663a0

[32]

RUBIN L J. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol)[J]. Ann Intern Med,1990,112(7):485. doi: 10.7326/0003-4819-112-7-485

[33]

O'CALLAGHAN D S, SAVALE L, MONTANI D, et al. Treatment of pulmonary arterial hypertension with targeted therapies[J]. Nat Rev Cardiol,2011,8(9):526-538. doi: 10.1038/nrcardio.2011.104

[34]

TUDER R M, COOL C D, GERACI M W, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension[J]. Am J Respir Crit Care Med,1999,159(6):1925-1932. doi: 10.1164/ajrccm.159.6.9804054

[35]

KEIL A, BLOM I E, GOLDSCHMEDING R, et al. Nitric oxide down-regulates connective tissue growth factor in rat mesangial cells[J]. Kidney Int,2002,62(2):401-411. doi: 10.1046/j.1523-1755.2002.00462.x

[36]

EMERSON M, MOMI S, PAUL W, et al. Endogenous nitric oxide acts as a natural antithrombotic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature[J]. Thromb Haemost,1999,81(6):961-966. doi: 10.1055/s-0037-1614607

[37]

RAJA S G. Endothelin receptor antagonists for pulmonary arterial hypertension: an overview[J]. Cardiovasc Ther,2010,28(5):e65-e71. doi: 10.1111/j.1755-5922.2010.00158.x

[38]

HIRATA Y, EMORI T, EGUCHI S, et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells[J]. J Clin Invest,1993,91(4):1367-1373. doi: 10.1172/JCI116338

[39]

MICHEL R P, LANGLEBEN D, DUPUIS J. The endothelin system in pulmonary hypertension[J]. Can J Physiol Pharmacol,2003,81(6):542-554. doi: 10.1139/y03-008

[40]

GODINAS L, GUIGNABERT C, SEFERIAN A, et al. Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword? Semin Respir Crit Care Med,2013,34(5):714-724. doi: 10.1055/s-0033-1356494

[41]

张桐桐, 薛春源, 吴洋, 等. 肺动脉高压发生机制及其药物治疗[J]. 心血管外科杂志(电子版), 2019, 8(2):217.

[42]

JULIAN L D, OLSON M F. Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions[J]. Small GTPases,2014,5:e29846. doi: 10.4161/sgtp.29846

[43]

LIU R, WOLINSKY J B, WALPOLE J, et al. Prevention of local tumor recurrence following surgery using low-dose chemotherapeutic polymer films[J]. Ann Surg Oncol,2010,17(4):1203-1213. doi: 10.1245/s10434-009-0856-z

[44]

DO E Z, FUKUMOTO Y, TAKAKI A, et al. Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension[J]. Circ J,2009,73(9):1731-1739. doi: 10.1253/circj.CJ-09-0135

[45]

石自福, 周其全, 马三丁, 等. 某部抗震救灾官兵高原脱适应情况调查[J]. 解放军预防医学杂志, 2011, 29(2):114-115. doi: 10.13704/j.cnki.jyyx.2011.02.023

[46]

THOM S R. Oxidative stress is fundamental to hyperbaric oxygen therapy[J]. J Appl Physiol (1985),2009,106(3):988-995. doi: 10.1152/japplphysiol.91004.2008

[47]

ZHOU Y, LIU X H, QU S D, et al. Hyperbaric oxygen intervention on expression of hypoxia-inducible factor-1α and vascular endothelial growth factor in spinal cord injury models in rats[J]. Chin Med J (Engl),2013,126(20):3897-3903.

[48]

HUANG Z X, KANG Z M, GU G J, et al. Therapeutic effects of hyperbaric oxygen in a rat model of endothelin-1-induced focal cerebral ischemia[J]. Brain Res,2007,1153:204-213. doi: 10.1016/j.brainres.2007.03.061

[49]

彭兆云, 杜晶, 孙学军, 等. 高压氧暴露诱导小鼠低氧耐受状态变化[J]. 中国职业医学, 2006, 33(1):7-8. doi: 10.3969/j.issn.1000-6486.2006.01.003

[50]

崔建华, 李彬, 张西洲, 等. 高压氧预处理对急性低氧大鼠心肌超微结构和心功能保护机制的研究[J]. 中华航海医学与高气压医学杂志, 2008, 15(5):276-278. doi: 10.3760/cma.j.issn.1009-6906.2008.05.006

[51]

XING R R, LIU K, JIAO T F, et al. An injectable self-assembling collagen-gold hybrid hydrogel for combinatorial antitumor photothermal/photodynamic therapy[J]. Adv Mater,2016,28(19):3669-3676. doi: 10.1002/adma.201600284

[52]

PARUMASIVAM T, CHANG R Y, ABDELGHANY S, et al. Dry Powder inhalable formulations for anti-tubercular therapy[J]. Adv Drug Deliv Rev,2016,102:83-101. doi: 10.1016/j.addr.2016.05.011

[53]

KLEEMANN E, SCHMEHL T, GESSLER T, et al. Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability[J]. Pharm Res,2007,24(2):277-287. doi: 10.1007/PL00022055

[54]

GUPTA N, AL-SAIKHAN F I, PATEL B, et al. Fasudil and SOD packaged in peptide-studded-liposomes: Properties, pharmacokinetics and ex-vivo targeting to isolated perfused rat lungs[J]. Int J Pharm,2015,488(1-2):33-43. doi: 10.1016/j.ijpharm.2015.04.031

[55]

PARANJPE M, NEUHAUS V, FINKE J H, et al. In vitro and ex vivo toxicological testing of sildenafil-loaded solid lipid nanoparticles[J]. Inhal Toxicol, 2013, 25(9): 536-543. https://pubmed.ncbi.nlm.nih.gov/23905970/.

[56]

PARANJPE M, FINKE J H, RICHTER C, et al. Physicochemical characterization of sildenafil-loaded solid lipid nanoparticle dispersions (SLN) for pulmonary application[J]. Int J Pharm,2014,476(1-2):41-49. doi: 10.1016/j.ijpharm.2014.09.031

[57]

ISHIHARA T, TAKAHASHI M, HIGAKI M, et al. Prolonging the in vivo residence time of prostaglandin E(1) with biodegradable nanoparticles[J]. Pharm Res,2008,25(7):1686-1695. doi: 10.1007/s11095-008-9549-8

[58]

ISHIHARA T, HAYASHI E, YAMAMOTO S, et al. Encapsulation of beraprost sodium in nanoparticles: analysis of sustained release properties, targeting abilities and pharmacological activities in animal models of pulmonary arterial hypertension[J]. J Control Release,2015,197:97-104. doi: 10.1016/j.jconrel.2014.10.029

[59]

BECK-BROICHSITTER M, KLEIMANN P, GESSLER T, et al. Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb Pro: formulation aspects and nanoparticle stability to nebulization[J]. Int J Pharm,2012,422(1-2):398-408. doi: 10.1016/j.ijpharm.2011.10.012

[60]

AKAGI S, NAKAMURA K, MIURA D, et al. Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension[J]. Int Heart J,2015,56(3):354-359. doi: 10.1536/ihj.14-338

[61]

GUPTA N, PATEL B, AHSAN F. Nano-engineered erythrocyte ghosts as inhalational carriers for delivery of fasudil: preparation and characterization[J]. Pharm Res,2014,31(6):1553-1565. doi: 10.1007/s11095-013-1261-7